39 results about "Amnion" patented technology

The invention discloses a composite amnion for improving contracture after tissue repair and a preparation method of the composite amnion. The composite membrane comprises a recombinant humanized collagen nanofiber membrane located in the middle layer and human decellularized amniotic membranes attached to the two faces of the nanofiber membrane. The composite membrane is prepared by preparing a recombinant humanized collagen nanofiber membrane through an electrostatic spinning technology and pressing the recombinant humanized collagen nanofiber membrane and a human decellularized amniotic membrane. The composite membrane has excellent mechanical properties and biological activity. Animal experiment results show that the composite film can effectively inhibit capsule contracture induced by radiotherapy, and the comprehensive effect of the composite film is obviously superior to that of a single-component material in the aspects of inflammation resistance, fibrosis resistance, degradation speed delaying, capsule compliance improving and the like. The composition can be used for improving the capsule contracture of the breast prosthesis, especially the capsule contracture induced by radiotherapy.

This disclosure generally relates to methods of preparing a graft for wound healing. In some embodiments, the methods comprise obtaining a donor placenta and isolating tissue comprising amnion and / or chorion from the donor placenta. In other embodiments, the methods comprise washing the isolated tissue with a cleansing solution. Other embodiments, still, are directed toward applying a current to the isolated tissue and / or cleansing solution to produce the graft for wound healing.

The utility model relates to the technical field of cervical cerclage, in particular to a cervical cerclage support for cervical insufficiency, which comprises a protective ring, a push rod, first connecting blocks, a fixing rod, a silica gel pad and a second connecting block, the push rod is slidably connected in the protective ring, the first connecting blocks are connected at the upper end of the push rod at equal intervals, and the fixing rod is connected with the silica gel pad. Fixing rods are rotationally connected to the first connecting blocks, silica gel pads are jointly connected between the fixing rods, and second connecting blocks are rotationally connected to the fixing rods. The fixing rod and the silica gel pad are installed, due to the fact that the amniotic sac is protected by the silica gel pad, the silica gel pad can effectively isolate direct contact between a suturing instrument and the amniotic sac, the softness and the elasticity of the silica gel pad can adapt to the shape of the amniotic sac, comprehensive protection is provided, and through protection of the silica gel pad, the suturing instrument can be prevented from being damaged. A doctor can perform suture operation more trustingly, the safety and success rate of an operation are effectively improved, and the operation risk is reduced.

The invention discloses a gynaecology and obstetrics intelligent visual midwifery system based on an ultrasonic technology, and relates to the technical field of ultrasonic midwifery, the system constructs a two-dimensional coordinate system and extracts ultrasonic echo total time and respiratory phase data, and fetal membrane structure data and fetal physiological data are generated through dimensionless processing and data analysis. And constructing an amniotic sac thickness gradient index dyn according to the thickness gradient change to evaluate the structural stability of the amniotic sac. And if the fetal respiratory phase drift index psh is evaluated to be unstable, calculating the fetal respiratory phase drift index psh, and jointly constructing a comprehensive parturition risk index Rco with the amniotic sac thickness gradient index dyn to reflect the potential parturition risk of coupling of the fetal stress level and the membrane structure variation. And the system generates different types of intervention instructions according to the evaluation result of the comprehensive parturition risk index Rco. Multi-dimensional data mapping and layer display are achieved, linkage display of a risk thermodynamic diagram and a breathing phase curve is supported, and a visual and traceable dynamic midwifery decision basis is provided for medical staff.

The invention discloses an amniotic epithelial cell-derived exosome for treating gestational hypertension and application thereof, and belongs to the technical field of biological medicines. The exosome (hAECs-exos) is obtained by secreting and extracting human amniotic epithelial cells (hAECs), the particle size distribution of the exosome (hAECs-exos) is 30-150 nm, and the exosome (hAECs-exos) expresses exosome specific markers CD9, CD63 and CD81. The invention also provides a preparation method of the exosome. The preparation method comprises the following steps: isolated culture of hAECs, and ultracentrifugal extraction and identification of the exosome. Animal experiments prove that when the exosome is applied to a gestational hypertension disease model animal in an intravenous injection mode, the blood pressure and urine protein level of the gestational hypertension disease model animal can be remarkably reduced, and the fetal rat dysplasia condition is improved. The invention provides a brand-new and effective biological preparation candidate scheme for the treatment of the gestational hypertension disease.

The invention relates generally to the fields of biology and health sciences. More particularly, the invention relates to compositions and methods for modulating cellular physiology and pathological processing using a combination of compounds that can be found in amniotic membrane tissue and umbilical cord tissue preparations.

The invention relates to the technical field of medical teaching devices, and discloses a cervical cerclage teaching practice device for simulating cervical insufficiency, which comprises a pig tripe water bag model and a base, and is characterized in that the pig tripe water bag model comprises an external wrapper for simulating cervical insufficiency and an internal filler for simulating an amniotic sac; the pylorus of the pig tripe in the model well simulates the special anatomical structure of the inner opening of the human cervix uteri and the texture of the human cervix uteri, meanwhile, the rubber sleeve simulates the state of the amniotic sac vividly, and the model vividly presents the state of incomplete cervix uteri functions. Meanwhile, the height of the base can be adjusted according to needs to adapt to trainees with different heights or simulate different cervix positions.

The invention relates generally to the fields of biology and health sciences. More particularly, the invention relates to compositions and methods for modulating cellular physiology and pathological processing using a combination of compounds that can be found in amniotic membrane tissue and umbilical cord tissue preparations.

This invention discloses an amniotic membrane mechanical tensile loading measurement device, relating to the field of membrane biomaterial research technology. It includes a fixed frame, a first clamping block assembly, a second clamping block assembly, a driving mechanism, and a monitoring device. The first and / or second clamping block assemblies are slidably disposed within the fixed frame, and the driving mechanism is fixedly disposed on the fixed frame. The driving mechanism can drive the first and second clamping block assemblies to move closer or further apart. Each clamping block assembly includes an upper clamping block, a lower clamping block, and a clamping locking mechanism. One of the upper and lower clamping blocks has a meshing groove, and the other has a meshing tooth. The two ends of the amniotic membrane are respectively fixed to the two clamping block assemblies. The clamping locking mechanism is a magnetic suction element. A microscope can be aligned with the amniotic membrane between the first and second clamping block assemblies. The monitoring device is used to monitor the operating parameters of the driving mechanism. This invention enables real-time in-situ observation in conjunction with a microscope and provides a stable clamping effect.

This invention relates to the field of obstetric nursing technology, and in particular to an obstetric nursing device for ruptured membranes with a negative pressure balancing function. The device includes an insertion tube, an endoscope fixedly mounted on the upper rear end of the insertion tube, and a membrane rupture assembly located at the rear end of the insertion tube. The membrane rupture assembly includes a baffle plate fixed to the rear end of the insertion tube, with multiple guide membrane holes inside the baffle plate. A blade groove is formed on the rear end face of the baffle plate, and a membrane rupture blade is movably mounted inside the blade groove. The baffle plate of this invention effectively blocks the fetus inside the amniotic sac, allowing the soft outer wall of the amniotic sac to enter the guide membrane holes, thus preventing damage to the fetus during membrane rupture. Simultaneously, the membrane rupture blade is located inside the insertion tube, ensuring that neither the fetus nor the mother is harmed during membrane rupture.

The invention relates generally to the fields of biology and life sciences. More particularly, the invention relates to compositions and methods for modulating cellular physiology and pathological processing using a combination of compounds that can be found in morselized amniotic membrane tissue and morselized umbilical cord tissue preparations.

A sterile micronized composition prepared from intact human placental tissue that is configured for wound healing. The sterile micronized composition includes micronized human amnion; micronized human chorion; and micronized human intermediate spongy layer. In certain aspects, the composition is prepared from intact placental tissue comprising a human amnion layer, human chorion layer, and an intact human intermediate spongy layer positioned between the human amnion layer and human chorion layer such that immediately before micronization the human amnion layer and the human chorion layer are not separated from one another.

The present invention relates to functionally improved epithelial stem cells. The epithelial stem cells with improved functionality by a method of the present invention are prepared without genetic modification, thus being less likely to cause side effects due to DNA delivery / modification, are derived from the amniotic membrane in which no tissue-compatible antigen (factor) is expressed, thus having no rejection, and exhibit improved cell migration and would healing effects due to the improved functionality. Therefore, the epithelial stem cells can be used for the regeneration of various tissues, including the cornea, amniotic membrane, skin, and the like, and particularly can be used for the prevention or treatment of premature rupture of the amniotic membrane.

Compositions comprising perforated, unseparated amnion / chorion; perforated, separated amnion; and perforated, separated chorion derived from the placenta and methods of preparing and using those compositions are provided. Perforation of placental tissue before or during processing may allow for one or more benefits such as more efficient removal of blood remnants, retention of wound healing and tissue regeneration components, better handling characteristics, or improved healing capacity. The present invention also includes methods of healing a wound of the skin, eye, nerve, tendon, or dura comprising applying the perforated compositions of the invention to the wound.

The invention provides an activity-enhanced amniotic membrane matrix as well as a preparation method and application thereof. According to the invention, on the basis of amniotic cells, genes for coding IL-4 and IL-22 growth factors are introduced into the amniotic cells by using a gene editing technology, and the genes are secreted outside cell membranes by using extracellular signal peptides, so that the filling material containing high-activity biological factors is prepared, the cell proliferation, migration and tissue regeneration are remarkably promoted, and the biological factors have good biocompatibility. The wound healing and tissue repairing processes are accelerated.

This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

Methods for producing extra-embryonic structures Described herein is a novel cell culture model of the post-gastrulation stage human amnion. Also described herein are methods for producing extra-embryonic structures in culture, in particular for producing an in vitro three-dimensional amnion model. The amnion models described herein, and amniotic membranes isolated from such amnion models, can be used in a variety of applications, such as in methods of drug screening, tissue engineering, regenerative medicine, wound healing and treating burns.

Cervical ripening catheters are disclosed, and methods for monitoring and measuring a change in intrauterine parameters without rupturing the amniotic sac. The catheter is provided with a uterine balloon, and a pressure sensor in pressure sensing communication with the uterine balloon. Sensing circuitry is configured to detect pressure applied to the pressure-sensor and communicate information relating to uterine contractions. The catheter may also be provided with sensors for determining fetal heart rate, oxygen saturation, respiratory rate, fetal blood pH or pelvimetry measurement. A working channel extends throughout the catheter to permit direct access to the amniotic sac by additional diagnostic or therapeutic tools.

The present invention provides a birth tissue derived implant for treating a subject. The birth tissue derived implant comprises a birth tissue and an agent exogenous to the birth tissue. The birth tissue is isolated from an amniotic sac, an umbilical cord or a placental plate. A method is also provided for repairing a defective tissue in a subject. The repair method comprises delivering the birth tissue derived implant to a surface of the defective tissue in the subject. The defective tissue may be an ocular membrane, a synovium, tendon, ligament, nerve, a cartilage or a bone. A method is further provided for preparing the birth tissue derived implant. The preparation method may comprise devitalizing or decellularizing a birth tissue from an amniotic sac, an umbilical cord or a placental plate, and adding an agent to the devitalized or decellularized birth tissue.

The invention relates to the technical field of stem cells, in particular to a preparation method of human placenta amnion pluripotent stem cells. The method specifically comprises the following steps: S1, tissue pretreatment and physical pre-layering; s2, carrying out mechanical-enzymatic synergistic dynamic dissociation; s3, gradient purification and washing; s4, performing soft matrix phenotype maintenance culture; according to the method disclosed by the invention, the separation efficiency of amniotic epithelial cells is improved and the enzyme exposure load is reduced through synergistic enzymolysis of Dispase II and Trypsin in combination with weak shearing force generated by the magnetic beads. Meanwhile, SB431542 blocks a signal channel to prevent EMT, a GelMA soft matrix maintains cell phenotypes, and Percoll density gradient centrifugation is matched to improve cell purity.

A sterile micronized composition prepared from intact human placental tissue that is configured for wound healing. The sterile micronized composition includes micronized human amnion; micronized human chorion; and micronized human intermediate spongy layer. In certain aspects, the composition is prepared from intact placental tissue comprising a human amnion layer, human chorion layer, and an intact human intermediate spongy layer positioned between the human amnion layer and human chorion layer such that immediately before micronization the human amnion layer and the human chorion layer are not separated from one another.

This present disclosure describes an amniotic membrane fetal tissue product with adhesive properties for use on an ocular surface to prevent or treat eye indications.

A stem cell-derived gastruloid model, its construction method, and its use are provided. The gastruloid model is constructed in vitro from human pluripotent stem cells and mimics, to some extent, biological events and major embryonic structures of early embryonic development, such as the development of primitive endoderm, the establishment of a bilayered blastocyst, the emergence of the amniotic cavity and amniotic cells, and the emergence of the primitive streak. It has been verified at both the protein and transcriptome levels. This model can better reproduce the major characteristics of the embryo from the peri-implantation stage to the gastrula stage. Furthermore, this model can be induced in batches for use as a screening model for drugs and environmental toxicants in early embryos, thereby providing safety testing for drug administration in specific clinical early pregnancy patients.

The invention relates to the technical field of stem cell engineering and anti-aging biology, in particular to a histone modification regulation method based on placenta amnion sub-totipotent stem cells and an anti-aging preparation thereof. The regulation and control method comprises the following steps: separating and purifying healthy full-month caesarean section placenta amniotic membrane tissues, carrying out composite enzymolysis and flow cytometry screening to obtain CD105 < + >, CD73 < + > and CD45 <-> stem cells, and primarily culturing the CD105 < + >, CD73 < + > and CD45 <-> stem cells; the method comprises the following steps: determining histone methyltransferase MLL3 and demethylase JMJD3 as target spots through ChIP-seq, and determining H3K4me3 and H3K27me3 as target modification sites; an MLL3 activator CM-272 with the final concentration of 15 [mu] M and a JMJD3 inhibitor GSK-J4 with the final concentration of 10 [mu] M form a composite regulator, and induction culture is performed for 84 h under the conditions of 37 DEG C and 5% CO2; and carrying out Western Blot verification and screening on the stem cells meeting the standard. According to the anti-aging preparation, regulated stem cells are used as active ingredients, a sodium alginate-gelatin (2: 1) composite carrier, 5% mannitol and 1% human serum albumin protective agent are used as auxiliary materials, and the injection with the pH of 7.2-7.4 is prepared. The method is accurate in regulation and control, and the preparation is remarkable in anti-aging effect and low in immunological rejection risk.

The utility model discloses a storage and taking device for a wet biological amnion. The storage and taking device comprises a protection tank and a storage box inserted into the protection tank, two height control assemblies are symmetrically installed on the left side and the right side of the protection tank, a temperature adjusting assembly used for temperature control is electrically connected into the protection tank, and clamping protection assemblies used in cooperation with the height control assemblies are slidably installed on the two sides of the temperature adjusting assembly. According to the wet biological amnion storage and taking device, the storage box and the protection tank are subjected to multiple sealing, the temperature is accurately controlled to be 2-8 DEG C through the temperature adjusting assembly, and the amnion storage time is prolonged; height control is matched with the clamping protection assembly, a ball screw is used for driving a sliding block to control a height adjusting block and an arc-shaped rotating plate, stable storage and taking are achieved, and transportation and operation shaking is reduced; the arc-shaped rotating plate and a rubber convex block of the temperature control base cooperate for damping, and the risk of vibration damage is reduced; a limiting window is matched with a light supplementing lamp to conveniently observe amniotic membrane conditions to adjust the environment.

Provided are a stem cell-derived gastruloid model, method for constructing same, and use thereof. The gastruloid model is constructed in vitro from human pluripotent stem cells, and simulated the biological events of early embryonic development and the key structures of the embryo to a certain extent, such as the development of primitive endoderm, the establishment of bilaminar germ disc, the appearance of the amniotic cavity and amniotic cells, and the appearance of the primitive streak and the like, which has been verified at both the protein level and the transcriptome level, and the key features of embryos from the peri-implantation period to the gastrula period could be well reproduced. This model can be induced in batches as a drug screening model for early embryos and environmental toxicants and the like, thereby providing safety testing for the use of drugs for certain clinical patients in early pregnancy and so on.

This invention discloses the application of MIF gene silencing in the preparation of drugs for treating premature rupture of membranes (PPROM), belonging to the fields of biomedicine and molecular biology. By collecting fetal membrane tissues from patients with PPROM and normal controls, this invention found that the expression level of MIF protein and the concentration of PGE2 were significantly increased in the PPROM group. Further investigation using siRNA technology to silence the MIF gene in human amniotic epithelial cells revealed that MIF silencing significantly reduced PGE2 levels. This invention is the first to demonstrate that MIF gene silencing can effectively treat PPROM by reducing PGE2 (inhibiting uterine contractions). This invention also provides a pharmaceutical composition containing MIF siRNA. This invention provides a novel molecular target and therapeutic strategy for the treatment of PPROM, with broad clinical application prospects.

This present disclosure describes an amniotic membrane fetal tissue product with adhesive properties for use on an ocular surface to prevent or treat eye indications.

The invention provides a precise nutrition regulation and control method for promoting intestinal development of young meat breeding chickens and application, belongs to the technical field of livestock and poultry breeding and production, and aims to solve the problem that hatching eggs laid by meat breeding chickens of 50 weeks old or above are insufficient in nutrition reserve, and L-methionine is injected through amniotic cavities when the meat breeding chickens are hatched to 17 embryonic ages. According to the method, the jejunum length, the jejunum weight and the ileum length (Plt: 0.05) of the 21-day-old offspring broiler chicken are remarkably increased, the expression of ileum proinflammatory factors (IL-8 and TNF-alpha) and apoptosis pathway genes (BAX, Caspase-3 and the like) is down-regulated, the expression of anti-apoptosis genes Bcl-2 is up-regulated, and the serum urea nitrogen level is reduced. Meanwhile, the daily average feed intake and the daily weight gain (Plt; 0.05) are improved. Through accurate intervention in the embryonic period, parent nutrition transfer limitation is broken through, the intestinal development and immune functions of offspring are improved, and an effective solution is provided for healthy breeding of offspring of elderly breeding hens.